Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-1701 in Previously Treated HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT06188559Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of BB-1701 in breast cancer, sponsored by Eisai Co., Ltd.. Started Apr 2024; status: completed.
02
Drugs
BB-1701
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06188559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188559.